Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
ALG3-associated congenital disorder of glycosylation (CDG) is a rare autosomal recessive metabolic disorder caused by defects in the ER mannosyltransferase activity. Affected individuals typically present with multisystem involvement, including neurological deficits, dysmorphic facial features, and variable skeletal anomalies. The disorder is characterized by a spectrum of clinical presentations ranging from severe developmental delay and microcephaly to intractable epilepsy and growth retardation. These clinical observations have been consolidated by a variety of independent studies that affirm the pathogenic role of ALG3 variants in CDG. Research findings have provided critical insights into both the natural history of the disease and the molecular mechanisms underlying its phenotype. The accruing evidence emphasizes the importance of a timely and accurate molecular diagnosis for guiding patient management and therapeutic interventions (PMID:23791010).
Multiple case reports and familial studies document autosomal recessive inheritance in ALG3-CDG. Segregation analyses in several unrelated families reveal a strong clustering of homozygous or compound heterozygous variants among affected individuals. In one notable report, probands from different families exhibited the variant c.286G>C (p.Gly96Arg) (PMID:26126960)—a finding that substantiates the genetic etiology of the disorder. The recurrent nature of such variants and the clear pattern of inheritance underscore the robust genetic association. Moreover, additional affected relatives in some pedigrees further support familial segregation and strengthen the evidence for causality. Such compelling genetic data reinforce the clinical validity of ALG3 mutations in the CDG spectrum.
Cohort studies utilizing multi‐patient analyses have expanded the genetic landscape of ALG3-CDG. These studies report that at least 24 probands have been diagnosed with ALG3 mutations, with several reports emphasizing similar phenotypic profiles such as microcephaly, seizures, and dysmorphic features (PMID:32389449). The genetic evidence comprises a diverse variant spectrum including missense, nonsense, and frameshift mutations. The identification of these alterations across independent studies and populations solidifies the role of ALG3 in the disorder. In addition, several of these investigations incorporate segregation analysis and detailed phenotypic characterization which further delineate the pathomechanism of the disease. This breadth of genetic evidence collectively supports a strong association between ALG3 mutations and the CDG phenotype.
Functional studies have provided complementary evidence by demonstrating that pathogenic variants in ALG3 lead to deficient enzyme activity and subsequent abnormal protein glycosylation. In vitro assays using patient-derived fibroblasts and rescue experiments have consistently shown reduced ALG3 expression and function, impairing the synthesis of properly glycosylated proteins (PMID:31067009). These functional deficits correlate well with the clinical presentation and biochemical profiles observed in patients. Animal and cellular models further recapitulate key features of CDG, underscoring the role of ALG3 in the glycosylation pathway. This experimental concordance confirms that the molecular defects observed are pathogenic and directly relevant to disease manifestation. Collectively, these studies provide moderate functional evidence in support of the gene-disease association.
To date, there is minimal conflicting evidence regarding the role of ALG3 in congenital disorder of glycosylation. Although a degree of phenotypic variability exists among patients, the core clinical features and genetic findings consistently align with ALG3 dysfunction. The lack of significant contradictory data and the reproducibility of both genetic and functional findings across diverse cohorts further consolidate the strength of the evidence. In-depth scrutiny of various reports shows no alternative genetic cause that could uniformly explain the observed phenotype. This consistency across studies bolsters confidence in the diagnostic utility of ALG3 molecular testing for CDG. Consequently, the convergent findings from clinical reports, genetic studies, and functional assays leave little doubt about the pathogenic role of ALG3 variants.
Key take‐home sentence: The integration of robust genetic data and concordant functional evidence firmly establishes ALG3 as a critical gene in the pathogenesis of congenital disorder of glycosylation, thereby supporting its use in diagnostic decision‑making and targeted therapeutic management.
Gene–Disease AssociationStrongAt least 24 probands have been reported across independent families demonstrating autosomal recessive inheritance with consistent clinical phenotypes including microcephaly, seizures, and dysmorphism (PMID:32389449) and supported by multi‑family segregation (PMID:26126960). Genetic EvidenceStrongMultiple case reports and cohort studies have identified homozygous and compound heterozygous mutations in ALG3, including the recurrent variant c.286G>C (p.Gly96Arg) (PMID:26126960), supporting a robust genetic association. Functional EvidenceModerateFunctional assays reveal reduced ALG3 enzyme activity with aberrant glycosylation profiles and rescue experiments confirming pathogenicity, consistent with the patient phenotype (PMID:31067009). |